Engene reports inducement grants under nasdaq listing rule 5635(c)(4)

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, “engene” or the “company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of april 2, 2025. the inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the company's common shares. the options each have an exercise price of $4.44 per share, which is equal to the closing price.
ENGN Ratings Summary
ENGN Quant Ranking